This press release is not intended for publication or distribution in the United States, Canada, Japan or Australia. MaaT Pharma…
Categorie
2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
February 6, 2023
MaaT Pharma Receives U.S. FDA Response Outlining Path Forward for Investigational New Drug Application for MaaT013 in Patients with Acute…
February 3, 2023
MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux Lyon, France, January 27, 2023 – 6:00pm CET…
January 27, 2023
MaaT Pharma Provides Corporate Update and Highlights Key Expected Milestones in 2023 Lyon, France, January 24, 2023 – 6:00 pm…
January 24, 2023
MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux Lyon, France, January 9, 2023 – 6:00…
January 9, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
January 6, 2023
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.